Canaccord Genuity Starts Furiex Pharmaceuticals (FURX) at Buy, Sees 112% Upside
Tweet
Share
E-mailGet Alerts FURX Hot Sheet
Price: $104.77 --0%
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Canaccord Genuity initiates coverage on Furiex Pharmaceuticals (NASDAQ: FURX) with a Buy and $45 price target.
The firm comments, "We are initiating coverage oF Furiex Pharmaceuticals (FURX) with a BUY rating and $45 price target. We like these type of stories that include a combination of: (1) highly visible cash-based valuation upside potential; (2) sizable pipeline opportunities that we think are underappreciated; (3) catalysts that can unlock value; and (4) a limited following that has the story off the radar of many. Our launch timing coincides with the Friday evening US approval of DPP-4 inhibitor Nesina (along with two combo drugs) by partner Takeda that we think can bring an inflection in the stock. Our $45 target implies 112% upside."
For an analyst ratings summary and ratings history on Furiex Pharmaceuticals click here. For more ratings news on Furiex Pharmaceuticals click here.
The firm comments, "We are initiating coverage oF Furiex Pharmaceuticals (FURX) with a BUY rating and $45 price target. We like these type of stories that include a combination of: (1) highly visible cash-based valuation upside potential; (2) sizable pipeline opportunities that we think are underappreciated; (3) catalysts that can unlock value; and (4) a limited following that has the story off the radar of many. Our launch timing coincides with the Friday evening US approval of DPP-4 inhibitor Nesina (along with two combo drugs) by partner Takeda that we think can bring an inflection in the stock. Our $45 target implies 112% upside."
For an analyst ratings summary and ratings history on Furiex Pharmaceuticals click here. For more ratings news on Furiex Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Piper Sandler Starts LightPath Technologies (LPTH) at Overweight
- Deutsche Bank Starts Hochtief AG (HOT:GR) (HOCFF) at Hold
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
